Guggenheim Lifts PT on Regeneron Pharmaceuticals (REGN) to $815 From $810

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the top most undervalued biotech stocks to buy now. Guggenheim analyst Yatin Suneja raised the firm’s price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $815 from $810 on August 4, keeping a Buy rating on the shares.

Why Regeneron Pharmaceuticals, Inc. (REGN) Crashed Last Week

A pharmacist in a lab coat carefully analyzing a vial of medicine for its quality.

The analyst told investors in a post-earnings note that the company’s fiscal Q2 performance exceeded investor expectations due to solid Dupixent sales and “a good performance from a struggling Eylea franchise.”

Suneja added that management made “some interesting comments on the call regarding BD strategy,” suggesting that Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is now open to considering “differentiated later-stage opportunities in areas with high unmet medical need” compared to its previous focus on early-stage assets.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company that develops, discovers, and commercializes therapies for several diseases, including cancer, eye disorders, and allergic conditions.

While we acknowledge the potential of REGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than REGN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.